(Q37796011)

23 August 2017

Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease (English)

1 reference

23 August 2017

0 references

1 reference

1 reference

1 reference

4

Anders Björklund

0 references

author name string

Ayse Ulusoy

series ordinal

1

1 reference

PubMed ID

20887871

23 August 2017

Mickael Decressac

series ordinal

2

1 reference

PubMed ID

20887871

23 August 2017

Deniz Kirik

series ordinal

3

1 reference

23 August 2017

1 January 2010

1 reference

Progress in Brain Research

23 August 2017

1 reference

23 August 2017

184

1 reference

23 August 2017

89-111

1 reference

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Alpha-synuclein and its neurotoxic fragment inhibit dopamine uptake into rat striatal synaptosomes. Relationship to nitric oxide.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Pathoanatomy of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Synthetic filaments assembled from C-terminally truncated alpha-synuclein.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

alpha-Synuclein is phosphorylated in synucleinopathy lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Novel tools for production and purification of recombinant adenoassociated virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Alpha-synuclein in Lewy body disease and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Molecular cloning of cDNA coding for brain-specific 14-3-3 protein, a protein kinase-dependent activator of tyrosine and tryptophan hydroxylases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Brain 14-3-3 protein is an activator protein that activates tryptophan 5-monooxygenase and tyrosine 3-monooxygenase in the presence of Ca2+,calmodulin-dependent protein kinase II

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Lack of nigrostriatal pathology in a rat model of proteasome inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Phosphorylation of synucleins by members of the Polo-like kinase family

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Glial reactions in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Structural determinants of PLD2 inhibition by alpha-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

A role for alpha-synuclein in the regulation of dopamine biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Multiplicity of infection/multiplicity of confusion

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Alpha-synuclein in Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Regulation of tyrosine hydroxylase by stress-activated protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

In vivo gene delivery for development of mammalian models for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Mutations in the lipid-binding domain of α-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Attenuation of dopamine transporter activity by alpha-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984005-1

7 January 2021

10.1016/S0079-6123(10)84005-1

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20887871